Navigation Links
Emerging Markets Present Challenge for Medical Device Companies Outsourcing Clinical Activities
Date:9/6/2013

CHAPEL HILL, N.C., Sept. 6, 2013 /PRNewswire/ -- It's no secret that the medical device sector sees emerging markets such as China and Brazil as their best opportunity for top-line growth over the next decade.

But to ensure their expansion into emerging markets, device companies will have to conduct more clinical activities in these high-growth countries so they can market their new products there. While some of the largest device companies have opened or announced plans to locate large research facilities in places like China and India, other organizations are using CROs or establishing small beach-head offices and using local resources.

Outsourcing is one of the tactics clinical leaders are using to expand their clinical programs into emerging markets. To help clinical leadership evaluate their organization's approach to outsourcing clinical activities, research and consulting leader Best Practices, LLC conducted a primary research study that analyzes factors associated with outsourcing clinical trial activities, such as cost, staffing, and quality.

The study, Clinical Affairs Excellence: Benchmarking Clinical Trial Strategies to Ensure Medical Device Success in a Global Marketplace, delivers hard-to-find external benchmarks on medical device clinical programs' presence in emerging markets, activities outsourced, staffing and budgets. Critical research objectives addressed in this study include:

  • Determine the regions where medical device organizations conduct clinical trials and percent of patients recruited annually from each region
  • Identify which Clinical Affairs activities are best suited to be outsourced or kept in-house
  • Gauge what the experience of peer device organizations has been relative to the cost of outsourcing clinical trial activities
  • Rate the value of benefits associated with outsourcing clinical trial activities 

The research found there is wide variance in the extent that medical device organizations have established clinical offices in emerging markets. But there appears to be consensus that if you have a clinical office or facility, you need to have company managers/leaders located there to guide clinical efforts.

"If your organization can support it, I'm a firm believer that having somebody on the ground is much more efficient operationally than trying to manage it remotely. But there's a cost benefit there or a cost that comes with having an infrastructure in those areas and it really would depend on the size of the company and the volume of work that they could do," said a clinical affairs director who participated in the study.

Research participants included 13 executives and managers from 11 medical device companies across a wide variety of therapeutic areas and product classes

To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www3.best-in-class.com/rr1232.htm.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
2. Device Sector Facing Medical Education Challenges as Industry Continues Expansion into Emerging Markets
3. Frost & Sullivan Analyzes Emerging Opportunities for Stakeholders in the Transforming Healthcare Industry
4. The Emerging Eastern European Market For Interventional Cardiology Devices Will Grow To $282 Million By 2021
5. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
6. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
7. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
8. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
9. Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
10. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
11. NextDocs Launches QuickStart for Emerging Growth Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):